BidaskClub downgraded shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) from a strong-buy rating to a buy rating in a research note issued to investors on Tuesday, July 11th.
JUNO has been the topic of a number of other reports. Zacks Investment Research downgraded shares of Juno Therapeutics from a buy rating to a hold rating in a report on Tuesday, May 2nd. FBR & Co restated a hold rating on shares of Juno Therapeutics in a report on Thursday, May 18th. Vetr downgraded shares of Juno Therapeutics from a buy rating to a hold rating and set a $28.85 price objective on the stock. in a report on Monday, June 26th. Citigroup Inc. decreased their price objective on shares of Juno Therapeutics from $34.00 to $30.00 and set a buy rating on the stock in a report on Tuesday, April 4th. Finally, Wedbush reiterated a neutral rating and issued a $24.00 price objective on shares of Juno Therapeutics in a report on Friday, May 5th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $30.86.
Juno Therapeutics (NASDAQ JUNO) opened at 28.90 on Tuesday. The company has a 50-day moving average of $28.51 and a 200-day moving average of $24.26. The firm’s market capitalization is $3.01 billion. Juno Therapeutics has a 1-year low of $17.52 and a 1-year high of $35.04.
Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by $0.24. The firm had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. Juno Therapeutics’s quarterly revenue was down 22.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.64) earnings per share. On average, equities analysts predict that Juno Therapeutics will post ($3.05) earnings per share for the current year.
In other news, Director Jay T. Flatley acquired 20,000 shares of the business’s stock in a transaction that occurred on Friday, May 26th. The stock was acquired at an average price of $24.76 per share, with a total value of $495,200.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the company’s stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $27.00, for a total transaction of $216,000,000.00. The disclosure for this sale can be found here. Insiders sold 8,041,500 shares of company stock worth $217,230,360 over the last 90 days. 15.26% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of the company. Great West Life Assurance Co. Can boosted its stake in Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 3,800 shares in the last quarter. Brighton Jones LLC purchased a new stake in Juno Therapeutics during the second quarter valued at $260,000. Nisa Investment Advisors LLC purchased a new stake in Juno Therapeutics during the first quarter valued at $200,000. CAPROCK Group Inc. purchased a new stake in Juno Therapeutics during the second quarter valued at $299,000. Finally, Russell Investments Group Ltd. purchased a new stake in Juno Therapeutics during the fourth quarter valued at $204,000. 64.60% of the stock is owned by institutional investors and hedge funds.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with our FREE daily email newsletter.